

CURRICULUM VITAE

I. Personal Information

Name

Parveen Shiraz, MD

Work Address

Stanford University
269 Campus Drive, CCSR 2205
Stanford, CA 94305
650-723-0837 (work)

Email

pshiraz@stanford.edu

II. Educational Background

University

06/1989-12/1993 Kilpauk Medical College, Chennai, India
Bachelor of Medicine, Bachelor of Surgery (MBBS)

Postgraduate Training

01/1994-01/1995 House Surgeon, Government Royapettah Hospital Chennai, India
Kilpauk Medical College Hospital, Chennai, India
06/1997-06/1998 Internship in Internal Medicine, Cedars-Sinai Medical Center
Los Angeles, CA
07/1998-06/2000 Residency in Internal Medicine, St. Mary's Medical Center
San Francisco, CA
06/2012-06/2015 Fellowship in Hematology and Medical Oncology
Loma Linda University, Loma Linda, CA
07/2015-06/2016 Fellowship in Blood and Marrow Transplantation
Stanford University, Stanford, CA

Board Certification

08/2000, 10/2010 Internal Medicine, ABIM
10/2015 Medical Oncology, ABIM
10/2015 Hematology, ABIM

Licensure

Medical Board of California Physicians and Surgeons Certificate #A067098 (active since 12/04/1998)
DEA Registration Certificate (active since 06/2000)

Clinical Practice

07/2000-09/2000 Hospital Medicine, Kaiser Permanente, Vallejo, CA
09/2000-09/2001 Internal Medicine, Kaiser Permanente, Gilroy, CA
09/2000-06/2012 Hospital Medicine Physician, Kaiser Permanente, San Jose, CA
08/2016-01/2019 Hematology/Medical Oncology, Kaiser Permanente, Redwood City, CA
Leukemia/Lymphoma Center of Excellence, Kaiser Permanente, Santa Clara, CA
02/2019-07/2021 Clinical Assistant Professor of Medicine, BMT-CT, Stanford University
08/2021-present Instructor of Medicine, BMT-CT, Stanford University
Post-doctoral Fellow, Shizuru Lab, Stanford University

III. Scholarly Publications

Original Refereed Papers, Published

Shiraz P, Payne KJ, Muffly L. The Current Genomic and Molecular Landscape of Philadelphia-like Acute Lymphoblastic Leukemia. *International Journal of Molecular Sciences* 2020 Mar; 21(6): 2193

Shiraz P, Jehangir W, Agrawal V. T-cell Acute Lymphoblastic Leukemia – Current Concepts in Molecular Biology and Management. *Biomedicines* 2021, 9(11), 1621. PMID 34829849

Fehrenbacher L, Capra AM, Quesenberry C, Fulton R, **Shiraz P**, Habel LA. Distant Invasive Breast Cancer Recurrence Risk in HER2+ T1a and T1b Node Negative, Localized Breast Cancer Diagnosed from 2000 to 2006. A Cohort from an Integrated Health Care Delivery System. *J Clin Oncol*. 2014 Jul 10;32(20):2151-8. Epub 2014 Jun 2. PMID: 24888815

Raza A, Cao H, Conrad R, Cobb C, Castelino-Prabhu S, Mirshahidi S, **Shiraz P**, Mirshahidi HR. Nuclear protein in testis midline carcinoma with unusual elevation of alpha fetoprotein and synaptophysin positivity: a case report and review of the literature. *Expert Rev Anticancer Ther*. 2015 Oct;15(10):1199-213. Epub 2015 Sep 1. PMID 26402248

Francis OL, Martinez SR, Milford TM, Baez I, Coats JS, Mayagoitia K, Concepcion KR, Ginelli E, Benitez A, Weldon, AJ, Arogyaswamy K, **Shiraz P**, Fisher R, Morris CL, Zhang XB, Filippov V, Van Handel B, Zheng Ge, Song C, Dovat S, Su RJ, and Payne KJ. A novel xenograft model to study the role of TSLP-induced CRLF2 signals in normal and malignant human B lymphopoiesis. *Haematologica*. 2015. Epub 2015 Nov 26. PMID 26611474

Muffly L, Lichtensztajn D, **Shiraz P**, Abrahao R, McNeer J, Stock W, Keegan T, Gomez SL. Adoption of Pediatric-Inspired ALL Regimens by adult oncologists treating adolescents and young adults: A population-based study. *Cancer* 2017 Jan 1; 123(1):122-130. Epub 2016 Sep 13. PMID 27622953

Lee CJ, **Shiraz P**, Muffly L. Pharmacologic maintenance strategies following allogeneic hematopoietic cell transplantation for acute myeloid leukemia. *Leuk Lymphoma* 2017 Mar;58(3):516-527. Epub 2016 Aug 11. PMID 27685315

Cappell K, Sundaram V, Park A, **Shiraz P**, Gupta R, Jenkins P, Periyakoil VSJ, Muffly L. Advance Directive Utilization is associated with less aggressive end of life care in patients undergoing allogeneic Hematopoietic cell transplantation. *Biology of Blood and Marrow Transplantation* 2018 Jan 31; PMID 29371107

Lemieux C, Muffly LS, Rezvani A, Lowsky R, Iberri D, Craig JK, Frank MJ, Johnston LJ, Liedtke M, Negrin R, Weng W, Meyer E, Shizuru J, **Shiraz P**, Arai S, Miklos D, Sidana S. Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma. *Bone Marrow Transplant* 2021 Feb;56(2):368-375. Epub 2020 Aug 11. PMID 32782351

Lemieux C, Johnston LJ, Lowsky R, Muffly LS, Craig JK, **Shiraz P**, Rezvani A, Frank MJ, Weng W, Meyer E, Shizuru J, Arai S, Negrin R, Miklos DB, Sidana S. Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukemia in the Era of Novel Agents. *Biology of Blood and Marrow Transplantation* 2020 Dec;26(12):e328-e332. Epub 2020 Sep 19. PMID 32961371

Baird JH, Frank MJ, Craig JK, Patel S, Spiegel JY, Sahaf B, Oak JS, Younes S, Ozawa M, Yang E, Natkunam Y, Tamaresis JS, Ehlinger Z, Reynolds WD, Arai S, Johnston L, Lowsky R, Meyer E,

Negrin R, Rezvani A, **Shiraz P**, Sidana S, Weng W, Davis KL, Ramakrishna S, Schultz L, Mullins CD, Jacob AP, Kirsch IR, Feldman SA, Mackall C, Miklos DB, Muffly L. CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma. *Blood* 2020 Dec 18; blood.2020009432. PMID 33512414

Dutta R, Miao SY, Phan P, Fernandez-Pol S, **Shiraz P**, Ho D, Mannis GN, Zhang TY. Epstein-Barr virus-positive lymphoproliferative disorder manifesting as pulmonary disease in a patient with acute myeloid leukemia: a case report. *J Med Case Rep*. 2021 Mar 28;15(1):170. PMID 33773605

Liang EC, Muffly LM, **Shiraz P**, Shizuru J, Johnston L, Arai S, Frank MJ, Weng W, Lowsky R, Rezvani A, Meyer EH, Negrin R, Miklos DB, Sidana S. Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. *Transplant Cell Ther*. 2021 Feb 25;S2666-6367(21)00713-2. PMID 33775587

Baird JH, Epstein DJ, Tamaresis JS, Ehlinger Z, Spiegel JY, Craig J, Claire GK, Frank MJ, Muffly L, **Shiraz P**, Meyer E, Arai S, Brown JW, Johnston L, Lowsky R, Negrin RS, Rezvani AR, Weng W, Latchford T, Sahaf B, Mackall CL, Miklos DB, Sidana S. Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma. *Blood Adv*. 2021 Jan 12;5(1):143-155. PMID 33570626

Complete list of published work in MyBibliography

<https://pubmed.ncbi.nlm.nih.gov/?term=Shiraz%2C%2BParveen%5BAuthor%5D&sort=date>

Book Chapter

Chandrika Gowda, Olivia L. Francis, Yali Ding, **Parveen Shiraz**, Sinisa Dovat, and Kimberly J. Payne. Pediatric High-Risk Leukemia - Molecular Insights. In, Leukemia – Various Types. Published Nov 11, 2015. ISBN 978-953-51-2202-9. Eds Margarita Guenova and Gueorgui Balatzenko. Intech Open Access.

IV. Meeting Abstract Presentations

Fehrenbacher L, Capra A, Quesenberry C, Fulton R, **Shiraz P**, Habel L. Distant Invasive Breast Cancer Recurrence Risk in HER2+ T1a and T1b Node Negative, Localized Breast Cancer, A Modern Population-Based Cohort. ASCO Annual Meeting, Chicago, 2011

Shiraz P, Francis O, Baez I, Conception K, Mayagoitia K, Ginelli E, Martinez S, Milford T, Coats J, Fisher R, Morris C, Zhang X, Ruijun S, Dovat S, Payne K, TSLP-induced alterations of multiple signaling pathways in primary CRLF2 B-ALL xenografts. ASH Annual Meeting, San Francisco, 2014.

Salcedo-Conception K, **Shiraz P**, Francis O, Milford T, Baez I, Payne K. Developing preclinical models to evaluate therapies for health disparities in childhood leukemia. Fourteenth Annual Health Disparities Research Symposium. Loma Linda University, 2014.

Mayagoitia K, Francis O, Baez I, Milford TA, **Shiraz P**, Payne K. Human TSLP activates the JAK2-STAT5 and PI3K/AKT/mTOR pathways in CRLF2 B-ALL cell lines. Fourteenth Annual Health Disparities Research Symposium. Loma Linda University, 2014.

Shiraz P, Francis O, Baez I, Salcedo-Conception K, Mayagoitia K, Ginelli E, Milford TA, Coats J, Fisher R, Morris C, Zhang X, Ruijun S, Payne K. Therapies for CRLF2 B-cell Acute Lymphoblastic

Leukemia. Western Regional Meeting of the American Federation for Medical Research, Carmel, 2015.

Shiraz P, Lichtensztajn D, Gomez SL, Keegan THM, Muffly LS. Uptake of pediatric-inspired acute lymphoblastic leukemia (ALL) regimens by adult oncologists treating adolescent and young adults (AYA): A population-based analysis across Northern California. ASCO Annual Meeting, Chicago, 2016

Shiraz P, Sidana S, Weng W, Jehangir W, Negrin RS, Miklos DB, Lowsky R, Rezvani A, Shizuru JA, Frank MJ, Meyer EH, Johnston L, Muffly, Arai S. Impact of Conditioning Regimen and Donor Type on Outcomes of Allogeneic Stem Cell Transplant for Myelofibrosis – a Single Institutional Experience. Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR, Digital, 2021

V. Clinical Research – Site (Stanford) Principal Investigator of the following clinical trials

05/2020 – 04/2021 A Randomized Trial of Alpha 1-Antitrypsin (AAT) for Treatment of High Risk Acute GVHD Following Hematopoietic Stem Cell Transplant (BMT CTN 1705).
Sponsor: NMDP NCT 04167514

07/2019 – 05/2021 Phase 1, Dose Escalation and Expansion Study of Engineered Donor Grafts Derived from Mobilized Peripheral Blood (OrcaGraft), with Single Agent Graft-Versus-Host Disease Prophylaxis in Recipients Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies.
Sponsor: Orca Biosystems, Inc. NCT 03802695

02/2020 – 06/2021 A Phase 2 Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination with Rituximab in Subjects with Refractory Large B-Cell Lymphoma (ZUMA-14). Sponsor: Kite Pharma, Inc. NCT 04002401

07/2020 – 06/2021 A Phase 1/2 Open-label, Multicenter Study of Lenzilumab and Axicabtagene Ciloleucel in Subjects with Relapsed or Refractory Large B-cell Lymphoma (ZUMA-19). Sponsor: Kite Pharma, Inc. NCT 04314843

VI. Laboratory Research

1996-1997 Metabolic Syndrome. PI – Dr. Gerald Reaven, MD, PhD
General Clinical Research Center, Stanford University Medical center
Processing patient blood samples

2013-2014 CRLF2 overexpressing Pre-B Acute Lymphoblastic Leukemia.
Supervisor – Dr. Kimberly Payne, PhD
Center for Health Disparity and Molecular Medicine, Loma Linda University
Skills learned include culture media preparation, tissue culture techniques, invitro studies of chemotherapy drugs, Flow cytometry sample preparation, processing and data analysis, ELISA procedure, protocol writing for invitro experiments. In vivo experiments involving mice injections (tail vein and intraperitoneal), collection and processing of mice blood, bone marrow and spleen.

2021-present CD117 Targeting Immunotherapy based Blood Stem Cell Transplant
PI – Dr. Judith Shizuru, MD, PhD
Invitro and invivo studies to evaluate CD117 targeting immunotherapy agents, without high dose chemo or radiotherapy, to eradicate diseased MDS stem cells and permit engraftment of healthy donor cells.

VII. Service to Professional Organizations

Membership

06/2011-present

American Society of Hematology

07/2013-present

American Society of Transplantation and Cell Therapy

Institutional Responsibilities

04/2019 – 08/2020 Director of Quality, Division of BMT/CT, Dept of Medicine, Stanford University

07/2019 – 07/2023 Assistant Program Director, BMT-CT Fellowship Program, Stanford University
